Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Files Patent Infringement Suit Against IONpath
SOUTH SAN FRANCISCO, Calif. , Sept. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has filed new legal action in the United States District Court
View HTML
Toggle Summary Fluidigm Revolutionizes Next-Generation Sequencing RNA Library Preparation with Microfluidic Automation
Fluidigm Launches Breakthrough RNA Sequencing Library Preparation Workflow, Delivering Substantial Cost Savings and Efficiency SOUTH SAN FRANCISCO, Calif. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve
View HTML
Toggle Summary Fluidigm Launches Imaging Mass Cytometry Immuno-Oncology Panel Kits and Advanced CyTOF Software at the 2019 World Molecular Imaging Congress (WMIC)
Fluidigm Showcases Immuno-Oncology Imaging Innovations at WMIC to Advance Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today
View HTML
Toggle Summary Fluidigm and the Icahn School of Medicine at Mount Sinai Collaborate on Landmark Single-Cell Study of the Human Epigenome
Mount Sinai selects Fluidigm single-cell microfluidics systems to identify epigenetic changes from environmental agents in study funded by the U.S. Department of Defense SOUTH SAN FRANCISCO, Calif. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
View HTML
Toggle Summary Fluidigm to Participate in Upcoming Health Care Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor
View HTML
Toggle Summary CORRECTING and REPLACING - Fluidigm Announces Second Quarter 2019 Financial Results
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass Cytometry Panel Kits, Advanced CyTOF Software Introduction of Nanoscale Automated RNA-Seq NGS
View HTML
Toggle Summary Jonathan Day Named VP, Commercial Operations, Americas
Seasoned Commercial Leader with Track Record in Life Sciences and Diagnostics SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Jonathan Day as Vice President, Commercial Operations, Americas .
View HTML
Toggle Summary Fluidigm to Automate RNA Sequencing Library Preparation Using Microfluidics Technology
Automated Nanoscale RNA Library Preparation for Next-Generation Sequencing to Deliver Significant Savings and Workflow Efficiency for the Molecular Laboratory SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools
View HTML
Toggle Summary Fluidigm Announces 3rd Annual Imaging Mass Cytometry User Group Meeting
Fluidigm Invites Researchers to the Largest Global Imaging Mass Cytometry Conference in Zurich, Switzerland SOUTH SAN FRANCISCO, Calif. , July 30, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Bill W. Colston Named to Fluidigm Board of Directors
Senior Biotechnology Leader with Broad Expertise in Life Science and Digital Health SOUTH SAN FRANCISCO, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Bill W. Colston to the company’s Board of Directors.
View HTML